KURA · CIK 1422143
What Kura Oncology, Inc. told the SEC could break it.
2 self-disclosed vulnerabilities, pulled from its own filings — each in the company’s words, with the source. This is the risk register almost nobody reads.
A limited set so far — we surface every cited disclosure we’ve extracted for KURA. More may follow as additional filings are processed.
In its own words
What could break it.
Geographic concentration
- China-based third-party manufacturing of KOMZIFTI and candidatesmedium
Kura owns no manufacturing and relies on third-party manufacturers and suppliers — including some in China — for commercial supplies of KOMZIFTI and clinical supplies of ziftomenib and darlifarnib, concentrating supply risk in outside (and partly Chinese) CMOs.
“We rely, and expect to continue to rely, on third parties, including manufacturers and suppliers located in China, for the manufacture of commercial supplies of KOMZIFTI and clinical supplies of ziftomenib and darlifarnib for preclinical and clinical testing.”
Regulatory & policy
- China trade restrictions / tariffs on manufacturers and suppliersmedium
International trade restrictions and tariffs could limit Kura's ability to work with its China-based manufacturers and suppliers or disrupt its supply chain, raising costs and threatening product-candidate development.
“Some of our manufacturers and suppliers are located in China. Recent developments in international trade policies, including restrictions and tariffs, may restrict our ability to work with certain of our manufacturers and suppliers or otherwise disrupt our supply chain, and we expect to experience increased costs and expenses, which may have adverse effects on the development of our product candidates and our business operations.”
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings — including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its suppliers
“In November 2022, we entered into a loan and security agreement with several banks and other financial institutions or entities party thereto, or collectively the Lenders, and Hercules Capital,”
Cited →Kyowa Kirin, Inc.
“If Kyowa Kirin does not fulfill its obligations under the co-promotion and medical affairs agreement that we entered into with Kyowa Kirin, Inc. in June 2025, or the Kyowa Co-Promotion Agreement, our business could be adversely affected.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch